A Multiple-Dose Study of Sinemet® CR (Carbidopa/Levodopa) in Healthy Subjects
NCT00460954 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20
Last updated 2008-08-14
Summary
The purpose of this clinical research study is to determine if different dosage regimens of Sinemet® CR (Carbidopa/levodopa) are dose proportional
Conditions
Interventions
- DRUG
-
Sinemet® controlled release (Carbidopa/levodopa)
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 50 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2007-06-30
- Completion
- 2007-08-31
Countries
- Canada
Study Locations
More Related Trials
-
Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease and Demonstrating Non-motor Symptoms of Wearing Off
NCT00642356 ·Status: TERMINATED ·Phase: PHASE4
-
Study to Evaluate SYN115 in Parkinson's Disease
NCT00605553 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess Pharmacokinetics of Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Parkinson's Disease Patients
NCT03576638 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes
NCT01617135 ·Status: COMPLETED ·Phase: PHASE2
-
A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's Disease
NCT00139880 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy
NCT00099268 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off
NCT01283594 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa
NCT02169453 ·Status: COMPLETED ·Phase: PHASE1
-
Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations
NCT01515410 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Carbidopa/Levodopa/Entacapone on Motor Function and Quality of Life in Patients With Parkinson's Disease
NCT00219284 ·Status: COMPLETED ·Phase: PHASE4
-
National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Neuroprotection Trial
NCT00063193 ·Status: COMPLETED ·Phase: PHASE2
-
Sinemet for Spasticity and Function in Amyotrophic Lateral Sclerosis and Primary Lateral Sclerosis
NCT03929068 ·Status: COMPLETED ·Phase: PHASE1
-
NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa
NCT05083260 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease
NCT00866502 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
NCT00357994 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome
NCT03235037 ·Status: COMPLETED ·Phase: NA
-
Effects of Monoamine Reuptake Inhibitor NS2330 in Parkinson's Disease
NCT00006077 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa
NCT02169479 ·Status: COMPLETED ·Phase: PHASE1
-
Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off
NCT00601978 ·Status: WITHDRAWN ·Phase: PHASE4
-
Multicenter Study of Rasagiline in Parkinson's Disease Patients Using Levodopa and Experiencing Motor Fluctuations
NCT00203034 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's Disease
NCT00558337 ·Status: COMPLETED ·Phase: PHASE2
-
An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects
NCT00914602 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study
NCT00590122 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)
NCT03887884 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa
NCT02774564 ·Status: COMPLETED ·Phase: PHASE1